Health

MangoRx launches oral Semaglutide weight loss treatment "Slim"

Article Image

Mangoceuticals (NASDAQ:MGRX) ("MangoRx"), a company specializing in men's health and wellness via telemedicine, announced today the launch of its oral Semaglutide weight loss treatment, marketed under the name "Slim."

This launch signifies a significant step for MangoRx's expansion into the weight management market.

Semaglutide, a GLP-1 receptor agonist, has gained recognition for its effectiveness in weight loss by regulating appetite according to the New England Journal of Medicine.

MangoRx's "Slim" is formulated as a convenient oral dissolvable tablet (ODT) with added Vitamin B6.

The company anticipates capitalizing on the rising demand for GLP-1 peptides like Semaglutide to grow revenue in the coming quarters.

With increasing awareness of GLP-1 treatments' efficacy in weight management, MangoRx believes it is well-positioned to capture this market growth and expand its telemedicine platform for direct-to-consumer sales.

Disclaimer
Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.
Publisher
Grafa